Corticobasal Syndrome

Corticobasal syndrome (CBS) is a rare, progressive neurodegenerative disorder characterized by markedly asymmetric motor and cortical dysfunction — combining rigid-akinetic parkinsonism with higher cortical features including limb apraxia, alien limb phenomenon, cortical sensory loss, and myoclonus. The use of "corticobasal syndrome" rather than "corticobasal degeneration" (CBD) is deliberate and clinically important: CBS is a clinical phenotype, not a single pathologic entity. At autopsy, classic CBD pathology accounts for less than 40–50% of patients presenting with CBS. The remainder have underlying Alzheimer disease (~20–25%), PSP (~15–20%), FTLD-TDP (~5–10%), or other pathologies including Lewy body disease, FUS, and even Creutzfeldt-Jakob disease. This pathologic heterogeneity makes CBS uniquely challenging — the syndrome-to-pathology mismatch is greater than for any other neurodegenerative parkinsonism.

Mean age of onset is 63 years, and estimated survival is 6–8 years from diagnosis. No disease-modifying therapies exist. Management is symptomatic and overlaps substantially with PSP, requiring multidisciplinary team care focused on maximizing function and quality of life.

Pathology and the Syndrome-Pathology Mismatch

Understanding that CBS is a clinical syndrome with heterogeneous underlying pathology is foundational to managing these patients.

Classic CBD Pathology

Corticobasal degeneration (CBD) is a 4-repeat tauopathy characterized by tau aggregates in both neurons and glia, with neurodegeneration of cortex (especially perirolandic) and subcortical regions (basal ganglia, thalamus, substantia nigra, subthalamic nucleus, red nucleus). The pathognomonic lesion is the astrocytic plaque — distinct from the tufted astrocyte of PSP. Other features include pretangles (more common than neurofibrillary tangles, in contrast to PSP and AD), oligodendroglial coiled bodies, and ballooned neurons immunopositive for αβ-crystallin and ubiquitin. Despite the asymmetric clinical presentation, cerebral atrophy at autopsy is often symmetric and widespread.

The tau filament structure in CBD differs from PSP, though both are 4R-predominant. The distribution and severity of tau pathology correlate with clinical phenotype: cortical-predominant CBD associates with classic CBS and frontal behavioral-spatial syndrome, whereas basal ganglia–predominant and PSP-like pathology associates with the PSP syndrome phenotype.

Pathologic Heterogeneity at Autopsy

Clinical Features

Motor Features (Basal Ganglia Signs)

The most common presenting complaint is early, asymmetric limb dysfunction — typically unilateral hand clumsiness or difficulty using one arm for complex tasks. Patients describe the limb as "not cooperating" or "having a mind of its own." The affected limb progressively develops fixed dystonic posturing (clenched fist, flexed wrist), rigid-akinetic parkinsonism, and eventually becomes functionally useless. The process then extends to the contralateral side, though asymmetry persists throughout.

The tremor in CBS is distinctive — a coarse, irregular rest-action tremor that differs from both the pill-rolling rest tremor of PD and the postural/action tremor of essential tremor. Stimulus-sensitive myoclonus is highly characteristic: brief, shock-like jerks triggered by tactile stimulation or voluntary movement (action myoclonus), often most prominent in the more affected limb. Additional motor features include hyperreflexia, extensor plantar responses (pyramidal signs), facial dystonia, and progressive gait impairment with postural instability — though gait and balance problems tend to occur later than in PSP.

The levodopa response in CBS is typically poor. However, a trial of levodopa up to 1000 mg/day for at least 1 month is recommended, as partial responses occur — particularly in patients with underlying PSP pathology (PSP-CBS overlap).

Cortical Features

Apraxia is the defining cortical feature and a core diagnostic criterion. Multiple types may coexist:

Limb-kinetic apraxia — loss of dexterity independent of modality, challenging to assess in the setting of rigidity and dystonia. Patients struggle with fine motor tasks (buttoning, using keys) out of proportion to their motor deficit.

Ideomotor apraxia — inability to perform a skilled motor task on command despite intact language and motor/sensory function. Testing: ask the patient to pantomime using a screwdriver, hammering a nail, hitchhiking, or waving goodbye. Errors include spatial and temporal distortions, body-part-as-object substitution, and movement simplification.

Orobuccal apraxia — difficulty performing learned oral movements (blowing out a match, coughing on command, licking lips on command) despite intact reflexive performance of the same actions.

Alien limb phenomenon occurs in approximately 30% of CBS patients. The affected limb exhibits involuntary, purposeful-appearing movements — grasping objects, undoing buttons that the other hand just fastened, or rising and interfering with voluntary tasks. Patients experience the limb as foreign or uncontrollable. This must include more than simple limb levitation or elevation, which can be confused with parietal drift. True alien limb includes a sense of estrangement and involuntary motor behavior. The phenomenon may also include "contralateral inhibition" — the alien limb actively interfering with the normal limb's actions.

Cortical sensory loss is present in approximately 25% at presentation. Testing includes agraphesthesia (inability to identify numbers drawn on the palm), astereognosis (inability to identify objects by touch), and sensory/visual neglect of the affected side.

Speech and Language

Speech impairment is common and may be a presenting feature — particularly progressive nonfluent aphasia (nfPPA) or apraxia of speech, which are increasingly recognized as prodromal manifestations of CBS or PSP-SL. Nonfluent aphasia involves effortful, agrammatic speech with impaired comprehension of complex grammatical structures. Apraxia of speech involves groping, self-correction, and articulatory errors with preserved comprehension. Both are strongly associated with 4R tau pathology.

Cognition and Behavior

Cognitive impairment is present in more than half of patients, though frank dementia is typically a later feature. The neuropsychological profile shows fronto-striatal-parietal deficits: impaired attention, verbal fluency, language, executive function, and visuospatial processing. Semantic memory is relatively preserved — a key differentiator from Alzheimer disease, though the presence of memory impairment does not exclude CBD pathology. Behavioral symptoms overlap with frontotemporal dementia: personality changes, apathy, irritability, disinhibition, antisocial behavior, and occasionally hypersexuality.

Diagnostic Criteria

2013 Armstrong Criteria

The Armstrong criteria identify four primary CBD phenotypes — recognizing that CBD pathology can present with any of these syndromes. Both probable and possible levels require insidious onset, gradual progression of ≥1 year, and age of onset >50 years (with or without family history or known genetic variant such as MAPT).

Imaging and Biomarkers

Structural MRI

Asymmetric frontoparietal cortical atrophy — particularly involving the perirolandic regions (pre- and post-central gyri) — is the hallmark imaging finding, contralateral to the clinically more affected side. This correlates with the lateralized motor and cortical signs. However, the absence of asymmetric atrophy does not exclude CBS. Despite the asymmetric clinical presentation, autopsy series show cerebral atrophy is often more symmetric and widespread than imaging suggests.

MRI also serves to exclude mimics: extensive chronic microvascular disease (vascular parkinsonism), hydrocephalus, mass lesions, and patterns suggestive of CJD (cortical ribboning on DWI, caudate/putaminal signal abnormality).

Functional Imaging

FDG-PET: Asymmetric hypometabolism of the frontoparietal cortex and basal ganglia, correlating with clinical lateralization. Frontotemporal involvement may also be present. More sensitive than structural MRI for detecting early changes.

DaT-SPECT: Often abnormal with reduced uptake correlating with contralateral parkinsonian features, but findings can be variable — presynaptic nigrostriatal function may be relatively preserved early in the disease, unlike PSP-RS where it is typically reduced earlier.

Tau PET

Tau PET in CBS remains experimental but holds promise. First-generation tracer ¹⁸F-flortaucipir (AV-1451) has limited utility for 4R tauopathies. Second-generation ¹⁸F-PI-2620 shows retention in putamen, globus pallidus, and cortical areas with better sensitivity and specificity for CBS — though performance is better in amyloid-positive than amyloid-negative patients, raising questions about how much signal comes from co-existing AD tau versus CBD tau. ¹⁸F-PM-PBB3 has also shown promise. Further validation is needed.

Amyloid Imaging and AD Biomarkers

Given that 20–25% of CBS has underlying Alzheimer disease pathology, amyloid PET is a valuable tool. A positive amyloid scan in a CBS patient strongly suggests AD (or AD + CBD) pathology. CSF biomarkers (low Aβ42, elevated p-tau217/p-tau181, elevated total tau) can similarly identify AD copathology. This has therapeutic implications as anti-amyloid therapies evolve.

Fluid Biomarkers

NfL: Elevated in CBS compared with PD, but cannot differentiate CBS from PSP or MSA. Useful for distinguishing atypical parkinsonisms from PD as a group.

CSF tau: Total and phosphorylated tau levels in CBS are low compared with AD but higher than in PSP. However, CSF tau cannot reliably differentiate CBS from PSP.

α-Synuclein SAA: Expected to be negative in CBS (a tauopathy). A positive result should prompt reconsideration of diagnosis — favoring Lewy body disease, PD, or MSA. Note that rare cases of CBS can have Lewy body pathology at autopsy.

Management

There is no disease-modifying therapy. The management approach for CBS is largely identical to PSP, as both conditions share the core challenge of progressive disability requiring multidisciplinary support. The care team should include neurology, PT, OT, speech-language pathology, neuropsychology, social work, dietetics, and neuropalliative care.

Disease-Modification Landscape

No disease-modification trials have been conducted specifically for CBS. Patients with CBS have been included in PSP trials (particularly those with PSP-CBS overlap), and all five major trials — NIPPS (riluzole), tideglusib, davunetide, PASSPORT (gosuranemab), and ARISE (tilavonemab) — were negative. The same barriers apply: late intervention, insufficient target engagement by anti-tau antibodies for intracellular pathology, outcome measure insensitivity, and the unique additional challenge of pathologic heterogeneity — enrolling patients with different underlying diseases (CBD, AD, PSP, FTLD-TDP) under one clinical syndrome inevitably dilutes treatment effects.

The pathologic heterogeneity of CBS actually presents a unique therapeutic opportunity: if underlying pathology could be identified in vivo using biomarkers (amyloid PET for AD, tau PET for 4R tauopathies, genetic testing for GRN/C9orf72, SAA for synucleinopathies), patients could be stratified to pathology-specific therapies. CBS patients with AD pathology might benefit from anti-amyloid or anti-tau therapies validated in AD. Those with 4R tau pathology could be enrolled in emerging tau-targeted trials (ASOs, tau vaccines, O-GlcNAcase inhibitors).

Prognosis

CBS carries a poor prognosis with estimated survival of 6–8 years from diagnosis. Death most commonly results from aspiration pneumonia, respiratory complications, and general debility. The rate of progression varies with underlying pathology: AD-type CBS may progress differently from CBD-type, though data are limited. Predictors of more rapid decline include early dysphagia, early bilateral involvement, and rapid functional deterioration. As with PSP, early integration of palliative care improves quality of life for patients and caregivers, and timely discussions of advance care planning, feeding tube decisions, and goals of care are essential.

References

1. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503.
2. Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 2014;85(8):925-929.
3. Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133(Pt 7):2045-2057.
4. Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676-685.
5. Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(3):182-192.
6. McFarland NR, Veilleux Carpentier A. Progressive supranuclear palsy and corticobasal syndrome. Continuum (Minneap Minn). 2025;31(4):1020-1050.